Update on FDA-EMA QbD Pilot
|
|
- Briana Barrett
- 5 years ago
- Views:
Transcription
1 Update on FDA-EMA QbD Pilot Presented by: Sharmista Chatterjee, PhD Branch Chief (Acting) Office of Process & Facility Office of Pharmaceutical Quality CDER, FDA Dolores Hernán, PhD Quality Office Specialized Scientific Disciplines European Medicines Agency
2 Presentation Overview FDA-EMA QbD Pilot Aim Scope Submission Process Communication timelines Q&As FDA-EMA Collaborative Research on QbD for Analytical Methods Next steps Concluding remarks 1
3 FDA-EMA Parallel Assessment Pilot Announced in March elopedandapproved/ucm pdf pdf Build on other harmonization programs FDA-EMA Joint Inspection Program Parallel FDA-EMA Scientific Advice Program Extended for 2 more years in March 2014 Applications can be accepted till March 2016 Japan participating as observer 2
4 EMA-FDA QbD pilot Aim Allow EU and US assessors exchange their views on the implementation of ICH Q8-Q10 using actual applications and facilitate harmonisation. Share knowledge gained with the EU network and Industry through lessons learnt. Scope Submissions that include an enhanced approach to pharm. development leading to at least one of the following: Design Space, PAT tools for control, Continuous process verification, Models to support real time release testing Continuous processes Post-approval regulatory flexibility 3 3
5 Participation Participation in the pilot is voluntary. Standard EMA and FDA submission requirements apply. Types of applications: MAAs/NDAs Type II Variations/sNDAs Scientific Advice/CMC meeting requests 4
6 Modalities: 2 options Parallel assessment: 1 application completed The application is submitted to both agencies at the same time, for parallel evaluation by both agencies. Consultative advice: 9 completed Several on-going The application is submitted to either EMA of FDA, and the agency doing the evaluation requests to obtain consultative advice from the other agency. The application is submitted to both agencies but NOT at the same time. Type of products Chemicals There are some informal interactions on biologicals as well. The legal EMA and FDA submission requirements apply 5 5
7 Process for Submission to the Pilot Parallel Assessment Interested applicants and sponsors should notify both agencies in writing three months prior to submission of an application. Application is submitted for assessment concurrently to both agencies: FDA: EMA: Consultative Advice Application is submitted to only one agency. Depending of the precedence setting nature of the QbD elements in the application, the reviewing agency seeks consult from the other agency. * US specific: applicants need to provide a letter allowing sharing of trade 6 secret and confidential information between agencies.
8 Communication Timelines for Parallel Assessment Evaluation Days (Standard) Clock Stop Day Clock Stop 210 Opini on NDA Receipt Initial TCdiscuss review and inspection Interim TC TC Discuss IR/ LoQs Exchange Draft Reviews and Questions List of Questions/ Information Requests Sent to Applicant Applicant Response Exchange Comments, Discuss Deficiencies via Telecon Complete & Exchange Review of Applicant Responses EMA-FDA Lessons Learned Telecon Review Month Standard) Post Action Filing Meeting 74 Day Letter Midcycle Meeting 7 Primary Review Completion Target Action Date 7
9 Communication Timelines for Consultative Advice Triggered by the Agency that has received the application. Timelines defined by the Agency receiving the application, upon consultation with the other Agency. The other agency: -Peer reviews AR/LoQ/IR. -Attends review discussions and provides input. -Attends meetings with applicants as an observer. 8
10 Outcome One of the projected outcomes of the pilot: Joint presentations of key findings will be presented publically through conferences and/or publications, as appropriate Findings have been jointly presented via: Multiple international conferences Three Q&A documents 9
11 Q&A Documents Jointly published by both EMA and FDA Based on learning's from the first parallel assessment application Includes comments from PMDA Objective: To serve as a reviewer guide Communication to industry/academia Method of publishing: FDA : Web updates EMA : Press release Publication timelines: Q&A Set (1) published on Aug 20, 2013 Q&A Set (2) published on Nov 1, 2013 Q&A Set (3) published on Dec 19,
12 Q&A (1) QTPP and CQAs Include in the submission: A list describing the QTPP of finished product and a rationale that links it to the intended use of the product (e.g. target patient population); CQA of drug substance and drug product and its role in the control strategy Criticality Based on impact (severity) not on the residual risk after the implementation of the control strategy Use only ICH supported terms Level of detail in manufacturing process descriptions The manufacturing process description should be adequately detailed and include all relevant parameters (both critical and non critical) with their target values or ranges. Describe steps in a sequential manner including batch size(s) and equipment type 11
13 Q&A (1) Cont. QbD for Analytical Method Analytical Target Profile acceptable as a qualifier of method performance. Not acceptable to switch between methods that have same ATP but different operating principles, without any regulatory over sight. Requirements to justify and support a MODR (Method Operable Design Region) is similar to that of a Design Space. This would include data to support proposed MODR ranges/conditions and demonstration of statistical confidence throughout the MODR. 12
14 Design Space verification Q&A (2) Includes discussions on: Necessity of verification of design space over the product life cycle Typically, initial verification of design space at commercial scale occurs at or near the target operating ranges Approach to verify a design space, dependent on: Risk of scale up Ability of control strategy to detect potential product failures Documentation of plan for design space verification FDA expectation is that plans be available at the manufacturing site EU expectation is that a protocol for design space verification be included in the dossier 13
15 Q&A (3) Level of detail regarding Risk Assessment (RA) Factors considered to determine requested level of detail include: significance of the outcome of the RA to the control strategy, complexity of the dosage form, amount of commercial scale data available at the time of submission. For example RA to identify parameters in order to establish a design space is considered of high significance. Level of detail regarding Design of Experiments (DOEs) and Design Space Level of detail for a DOE commensurate with significance of outcome of DOE to define the control strategy. Level of detail for a design space is dependent on significance of the design space and its extent. Mathematical regression model to define a design space is not always needed. 14
16 FDA-EMA Collaborative Research on QbD for Analytical Methods Joint research with FDA s laboratory/review divisions and EMA Initiated in January, 2013 Goal of this project is to: Develop analytical methods (e.g. HPLC) based on QbD paradigm. Define protocols for method transfer. Establish methodology for validation of MODR upon site transfer. Define review criteria for evaluation of QbD based analytical methods. 15
17 Next Steps Ongoing work to make the process easier for applicants and assessment / review teams. Several consultative advice applications ongoing, including Newer/novel technologies Continuous manufacturing Additional Q&A will be drafted if needed based on learnings from on-going consultative advice applications. 16
18 Concluding Remarks Are we there yet? No, BUT progress is being made. Very useful interactions. Pilot: established platform for continuous dialogue between the Agencies. Process improvements to facilitate interaction with Industry during the pilot process already in place for the next application. What is the benefit for industry? Short term: Unrealistic to expect full convergence, e.g. 100% harmonisation in IR/LoQs at once, but some convergence was reached already. Lessons learned at the end of each evaluation to be made public Share knowledge; better guidance on how to prepare dossiers. Long term: Harmonization in regulatory requirements, where possible. What to expect, when being part of the pilot? No procedural delays in approval timelines due to quality / CMC issues. The pilot is resource intensive for Regulators. Need for flexibility in providing responses to the Agencies (the regional RA departments in companies need to coordinate). 17
19 To discuss your new drug QbD submission in US: Contact the Clinical Division and/or CMC Project Manager to request a meeting Address general questions to: newdrugcmc@fda.hhs.gov 18
20 Acknowledgements: EU PAT Team: J-L Robert, K.Pugh, EU PAT Team EMA: E. Korakianiti, A.M. Van Nederkassel US FDA: C. Moore, D. Henry, ONDQA staff 19
21 Thank you for your attention! 20
Quality Risk Management ICH Q9
Quality Risk Management ICH Q9 Executive summary for competent authorities and industry Disclaimer: This presentation includes the author s views on quality risk management theory and practice. The presentation
More informationGuidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA
Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this
More informationRemediation, Resolution and Outcomes
IPA Pharmaceutical Forum 2018 22-23 February 2018 Presented by Andrei Spinei Manufacturing and Quality Compliance, European Medicines Agency An agency of the European Union Contents 1.EMA EU Network 2.Remediation
More informationBASG / Austrian Medicines and Medical Devices Agency Institute Assessment & Analytics Traisengasse 5, A-1200 Vienna
This guidance document is intended to provide applicants with detailed information on the operational procedure of National Scientific Advice (NASA) by the Austrian Federal Office for Safety in Health
More informationWork plan for GCP Inspectors Working Group for 2018
22 March 2018 EMA/87812 /2018 Committees and Inspections Chairperson: Ana Rodriguez The activities outlined in the work plan for 2018 have been agreed in view of preparation for the Agency s relocation
More informationQ11 Development and Manufacture of Drug Substances--Questions and Answers
This document is scheduled to be published in the Federal Register on 02/26/2018 and available online at https://federalregister.gov/d/2018-03809, and on FDsys.gov 4164-01-P DEPARTMENT OF HEALTH AND HUMAN
More informationOfficial Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10
Official Integrated Implementation Training Workshops for ICH Q8, Q9 and Q10 Presented by 26-27 September, 2011 Government Conference Centre 2 Rideau Street (opposite Chateau Laurier) Ottawa, ON K1N 8X5
More informationPatient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force
5 May 2017 EMA/180341/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Patient Registry Initiative- Strategy and Mandate of the Cross-Committee Task Force EMA Initiative 1.
More informationPMDA EPOCH Toward 2020
PMDA International Vision PMDA EPOCH Toward 2020 As one of the world s top three medical products regulatory agencies comparable to its American and European counterparts, PMDA aims to: 1. Secure the highest
More informationPDUFA V. New Review Program for NME NDAs and Original BLAs. Enhanced Communications with FDA and Sponsors. Beth Duvall
PDUFA V New Review Program for NME NDAs and Original BLAs Enhanced Communications with FDA and Sponsors Beth Duvall Assoc Director for Regulatory Affairs FDA/CDER/Office of New Drugs September 25, 2013
More informationThe place of the Certification procedure in 2017 in the EU regulatory framework and beyond. Prague, 19 September 2017
The place of the Certification procedure in 2017 in the EU regulatory framework and beyond Prague, 19 September 2017 Hélène BRUGUERA Head of the Certification Department, EDQM, Council of Europe CEPs in
More informationProgress Report in 2016
APAC Position Paper Progress Report in 2016 APAC RA-EWG Table of Contents INTRODUCTION 1 PROGRESS REPORT ON FOCUSED TOPIC(S) 3 IPMG (International Pharmaceutical Manufacturers Group) 3 JPMA (Japan Pharmaceutical
More informationTechnical Report No. 68 Risk-Based Approach for Prevention and Management of Drug Shortages
Technical Report No. 68 Risk-Based Approach for Prevention and Management of Drug Shortages Paradigm Change in Manufacturing Operations PDA Risk-Based Approach for Prevention and Management of Drug Shortages
More informationWhy do we need an addendum to ICH E6?
Addendum to ICH E6 Hideaki Ui, Ph.D. Inspection Director Office of Non-clinical and Clinical Compliance Pharmaceuticals and Medical Devices Agency, Japan Disclaimer The views and opinions expressed in
More informationSADC Collaborative Medicines Registration Initiative (Zazibona)
SADC Collaborative Medicines Registration Initiative (Zazibona) Dr Sinah Selelo Drugs Regulatory Unit Ministry of Health & Wellness GALVmed/OIE stakeholder workshop on the harmonisation of the registration
More informationGCP Inspection by PMDA
2012 EU GCP Inspectors Working Group Workshop London, 12-14 November 2012 Practical Experience in GCP inspections, non EU/EEA countries GCP Inspection by PMDA Kazuko Natsui Inspector for GCP Inspection,
More informationProcedure for handling applications for authorisation and review reports under REACH
Procedure for handling applications for authorisation and review reports under REACH 1. Purpose This procedure describes how to handle applications for authorisation (AfA) as established by the REACH Regulation
More informationStandard operating procedure
Standard operating procedure Title: Evaluation procedure for applications and requests for the establishment or review of Maximum Residue Limits (MRLs) Status: PUBLIC Document no.: SOP/V/4150 Lead author
More informationLessons from the EMA Patient Registries Initiative
Lessons from the EMA Patient Registries Initiative STAMP Commission Expert Group 8 th June 2018 Presented by Peter Arlett, with contributions from Patricia McGettigan and Jane Moseley Head of Pharmacovigilance
More informationTraining components for GCP. inspectors in PMDA. Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA
Training components for GCP inspectors in PMDA Tomonori Tateishi, MD, PhD Office of Conformity Audit, PMDA Content 1. Conformity inspection in the training program for newcomers to PMDA 2. The training
More informationQuestions and answers on the procedure of PIP compliance verification at EMA, and on paediatric rewards
15 December 2014 EMA/PDCO/179892/2011 Rev. 2 Product Development Scientific Support Paediatric Medicines Questions and answers on the procedure of PIP compliance verification at EMA, and on paediatric
More informationTomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan
Tomoko OSAWA, Ph.D. Director for GCP Inspection Office of Conformity Audit PMDA, Japan The views presented in this presentation are those of the author and should not be understood or quoted as being made
More informationAccelerated procedure for registration of WHO-prequalified medicines = Collaboration Procedure between the WHO Prequalification Programme and NMRAs
Accelerated procedure for registration of WHO-prequalified medicines = Collaboration Procedure between the WHO Prequalification Programme and NMRAs Lembit Rägo/Milan Smid WHO Prequalification of Medicines
More information- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation
- Proposal for a Regulation on HTA- Ioana Siska, MD, PhD DG SANTE - Health Systems and Products Medical Products: safety, quality, innovation Pharma Committee meeting, 8 March 2018 Background More than
More informationScientific Advice and Protocol Assistance at the EMEA
Univ.-Doz. Dr. Bernhard Fischer, MBA P.O. Box 4, A-1097 Vienna, Austria Phone: +43-(0)664-1432919 Fax: +43-(0)664-1477280 Mail: biotechconsulting@aon.at URL: www.biotechnologyconsulting.eu Regulatory Affairs
More informationTHE PREVENTIVE CONTROLS RULES AND THE FSPCA
THE PREVENTIVE CONTROLS RULES AND THE FSPCA Dr. Robert Brackett, Illinois Institute of Technology International Citrus & Beverage Conference Clearwater Beach, FL September 17, 2015 Food Safety Modernization
More informationEDQM roadmap for electronic submissions
EDQM roadmap for electronic submissions Cornelia Bigler Weber scientific assistant Certification Department, EDQM 19 September 2017 1 Agenda esubmissions Roadmap for CEP applications with its major changes
More informationIPEC- Americas Ongoing Projects
IPEC- Americas Ongoing s name IPEC- PDG Working group Hold technical meetings with PDG on as needed basis/meet yearly with PDG On- going monograph harmonization JECFA/Food Related Issues related to Mg
More informationEVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL TEXTS FOR USE IN THE ICH REGIONS
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationThe implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium. and impact on the ethical review process
1 The implementation of the Clinical Trial Regulation (CTR, n 536/2014) in Belgium and impact on the ethical review process 2 1. Clinical Trials on Medicinal Products for Human Use: Change of the Legal
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationLEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS
LEGISLATION UPDATE & STATUS OF MCC / SAHPRA and GUIDANCE TO MEET REGULATOR S EXPECTATIONS Joey Gouws MCC and Cluster: Food Control, Pharmaceutical Trade and Product Regulation NATIONAL DEPARTMENT OF HEALTH
More informationComplaints Investigation and Review. Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018
Complaints Investigation and Review Dr. Ademola Daramola International Relations Specialist Drugs US FDA India Office New Delhi February 22nd 2018 Information presented in this presentation does not represent
More informationGDUFA II: Requests for Reconsideration
GDUFA II: Requests for Reconsideration Priya Shah, Pharm.D. Immediate Office Project Manager Office of Regulatory Operations, Office of Generic Drugs Purpose To provide an overview of requests for reconsideration
More informationGLOBAL BIOANALYSIS CONSORTIUM on harmonization of bioanalytical guidance 2014, time for a status update
GLOBAL BIOANALYSIS CONSORTIUM on harmonization of bioanalytical guidance 2014, time for a status update presented by Peter van Amsterdam, for GBC at 5 th JBF meeting, 6 March 2014 Tokyo, Japan GBC 2010-2014
More informationFeedback on SADC Workshop of Industry & Regulators. Luther Gwaza PhD Consultant
Feedback on SADC Workshop of Industry & Regulators Luther Gwaza PhD Consultant SADC WORKSHOP ON REGISTRATION OF MEDICINES & GOOD MANUFACTURING PRACTICE STANDARDS 11 TH 13 TH APRIL 2016, SOUTH AFRICA Brief
More informationDr. R. Sathianathan. Role & Responsibilities of Principal Investigators in Clinical Trials. 18 August 2015
18 August 2015 Role & Responsibilities of Principal Dr. R. Sathianathan Professor of Psychiatry, SRMC, Porur & Former Director, Institute of Mental Health, Chennai Principal Investigators & GOOD CLINICAL
More informationConsideration on Global Harmonization
ICDRA Workshop I Consideration on Global Harmonization Oct. 25, 2012 Dr. Nobumasa Nakashima Director, Office of International Programs PMDA, Japan 1 Current Harmonization Activities ICH: International
More informationCertification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit
Certification Scheme for a Certificate of Pharmaceutical Product (CPP) IFPMA CPP Network Training Toolkit 01 Training package Why is training needed? Training modules CPP overview CPP scenario training
More informationAnnual report of the Good Clinical Practice Inspectors Working Group 2016
15 June 2017 EMA/INS/GCP/763873/2016 Committees and Inspections Annual report of the Good Clinical Practice Inspectors Working Group 2016 Adopted by the GCP IWG on 2 June 2017 30 Churchill Place Canary
More informationInternational trend on medical device regulatory convergence
International trend on medical device regulatory convergence Mari Shirotani, Ph.D. Division Director, Office of International Programs Pharmaceuticals and Medical Devices Agency (PMDA) 1st December, 2017
More informationGuidance for applicants requesting scientific advice
7 December 2017 EMEA/CVMP/SAWP/172329/2004 Rev. 5 Veterinary Medicines Division Introduction The Scientific Advice Working Party (SAWP-V) of the Committee for Medicinal Products for Veterinary Use (CVMP)
More informationISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan
ISO14155: 2011 Clinical investigation of medical devices for human subjects - Good Clinical Practice - ISO TC194 WG4 Madoka Murakami PMDA, Japan What is GCP? Good Clinical Practice (GCP) is an international
More informationImplementation of REACH & CLP: common challenges of national authorities and ECHA
Implementation of REACH & CLP: common challenges of national authorities and ECHA Finnish Safety and Chemicals Agency (Tukes); Opening Seminar 9 February 2011, Tampere Geert Dancet Executive Director Content
More informationICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY
ICH STEERING COMMITTEE October 24-29, 2009 St. Louis, MO, USA SUMMARY 1. Opening Discussions The ICH Steering Committee (SC) meeting was chaired by the FDA. The meeting commenced with the provision of
More informationGuidance for Industry
Guidance for Industry Self-Identification of Generic Drug Facilities, Sites, and Organizations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationReceived an RTA Deficiency List or AI Letter? Now What?
Received an RTA Deficiency List or AI Letter? Now What? Dealing with Unexpected Issues/Questions during the Submission Review Process Navigating Submission Challenges to reduce time & risk September 26,
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Corrective and Preventative Action SOP-QMS-008 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s)
More informationRegional Update ASEAN PPWG
Regional Update ASEAN by Yuppadee JAVROONGRIT, Ph.D. Co-Chair of ACCSQ/, ASEAN Drug Control Division, FDA, Thailand The ICH-Global Cooperation Group Meeting Portland Marriott Downtown Waterfront Hotel,
More informationA guide to PDUFA V. Focus US update. Regulatory Rapporteur Vol 9, No 11, November 2012
10 A guide to PDUFA V Authors Virginia Beakes-Read JD RN, Executive Director, Global Regulatory Policy and Intelligence, Eisai, Inc; Florence Houn MD MPH FACP, Vice President, Regulatory Policy and Strategy,
More informationCall for proposals on platform technologies: Frequently asked questions (FAQs) - 1
Coalition for Epidemic Preparedness Innovations Call for proposals on platform technologies: Frequently asked questions (FAQs) - 1 Submitted by 15 September 2017 Overview Below you will find answers to
More informationEuropean Patients Academy (EUPATI) Update
European Patients Academy (EUPATI) Update EMA meeting with patient/consumer organisations 11 Dec 2013 Maria Mavris EURORDIS // EUPATI WP4 Co-Lead For patient-centric medicines R&D and to contribute to
More information<Insert Picture Here> Some Background and What You Should Know and Do Now to Prepare
1 E2B (R3): Some Background and What You Should Know and Do Now to Prepare The following is intended to outline our general product direction. It is intended for information purposes
More informationFirst inspection of a Legal Representative in the EU by local authority
First inspection of a Legal Representative in the EU by local authority Michael Gierend, DVM PhD on behalf of Edgar Fenzl, MD, PhD FGK Representative Service GmbH ( www.fgk-rs.com ) Munich, Germany CEMO
More informationICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter. Step 3
European Medicines Agency December 2008 EMEA/CHMP/ICH/645408/2008 ICH Topic Q4B Annex 6 Uniformity of Dosage Units General Chapter Step 3 ANNEX 6 TO NOTE FOR EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationGeneral FAQ relating to e-submission for Veterinary Applications
Veterinary Harmonisation Group July 2017 General FAQ relating to e-submission for Veterinary Applications 1. GENERAL QUESTIONS 1.1. What is an electronic submission for veterinary medicinal products? 1.2.
More informationUnofficial copy not valid
Page 2 (9) CONTENTS 1. PURPOSE... 3 2. DEFINITIONS... 3 3. RESPONSIBILITY... 3 4. INVESTIGATOR SELECTION... 3 4.1 Identification of Investigator s... 3 4.2 Initial Contacts... 4 4.3 Distribution of Pre-Study
More informationRole and Vision of PMDA
Role and Vision of PMDA ~Promoting Global Public Health~ Taisuke Hojo Senior Executive Director Pharmaceutical and Medical Devices Agency (PMDA) 1 st Malaysia-Japan Symposium March 10 th, 2015 Today s
More informationPOSTGRADUATE DIPLOMA/MSc IN PHARMACEUTICAL MEDICINE
POSTGRADUATE DIPLOMA/MSc IN PHARMACEUTICAL MEDICINE 2018/2020 University of Dublin, Trinity College Index Introduction... 1 Aims... 1 Intended Participants... 1 Course Structure... 2 Course Content and
More informationNEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use EMEA/267187/2005/ Rev. 1 London, 26 April 2006 NEW FRAMEWORK FOR SCIENTIFIC ADVICE & PROTOCOL ASSISTANCE The CPMP/CHMP
More informationmanaging or activities.
STANDARD OPERATING PROCEDURE Clinical Research Monitoring TITLE: Site Initiation Visit TITLE: Site Initiation Visit 1. PURPOSE SOP Number: Version: 1.0 MICHR CRM MON 002 Effective Date: 19Dec2013 1.1 This
More informationEvaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes
Evaluating adverse events from patient support and market research programs: proposed best practices and regulatory changes 2 nd Adverse Event Reporting and Safety Strategies Summit December 8-9, 2015
More informationEffective Date: 11/09 Policy Chronicle:
Title: Investigational Drug Service Functions Policy Type: Clinical Operations Replaces (supersedes): Title: N/A Policy Chronicle: Date Original Version of Policy was Effective: 09/06 Reviewer Signature:
More informationRegional Update ASEAN PPWG
Regional Update ASEAN PPWG by Yuppadee JAVROONGRIT, Ph.D. Co-Chair of ACCSQ/PPWG, ASEAN Drug Control Division, ThaiFDA, Thailand The ICH-Global Cooperation Group Meeting Yokohama Royal Park Hotel, Yokohama,
More informationAddendum to ICH E6 (R2)
Addendum to ICH E6 (R2) Stephanie Shapley (US FDA) - Rapporteur Dr. Fergus Sweeney (EMA) - Regulatory Chair Date: December 15, 2015 International Council for Harmonisation of Technical Requirements for
More information1 The EU Harmonised technical ectd guidance version 4.0
Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory ectd format for regulatory submissions (Status: Final version adopted by the esubmission CMB. Dated 26 July 2016) Scope This annex is
More informationQuestions and answers about Recycling Processes
Questions and answers about Recycling Processes 1. How do I apply for an authorisation for a plastic recycling process? 1. You should draw up an application following the European Food Safety Authority
More informationNew European Union Clinical Trial Regulations
New European Union Clinical Trial Regulations Incorporate Monitoring and Safety Reporting Techniques into U.S. and EU Clinical Trial SOPs Anita K. Murthy Deputy Director, Global Regulatory Affairs Bayer
More informationONADE s Data Quality Review
ONADE s Data Quality Review Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulatory Affairs in Animal Health Seminar Kansas State University Olathe March 06, 2018 Presenter: Ana
More informationOverview ICH GCP E6(R2) Integrated Addendum
2017 Biomedical Research Alliance of New York LLC CITI Program is a division of BRANY Overview ICH GCP E6(R2) Integrated Addendum Introduction On 15 December 2016, the International Council for Harmonistion
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE EVALUATION AND RECOMMENDATION OF PHARMACOPOEIAL
More informationICH Regulators Forum. Dr Peter Arlett EU
Dr Peter Arlett EU International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use In this presentation ICH Regulators Forum: Background ICH Regulators
More informationA Comparative Study of Registration Procedure for Submission of Generic Drug in Brunei Darussalam and Malaysia
Review Article A Comparative Study of Registration Procedure for Submission of Generic Drug in Brunei Darussalam and Malaysia *Gopal Patel, Dilip Maheshwari Department of Quality Assurance & Pharm Regulatory
More informationUse of disease registries for benefitrisk evaluation of medicines: A regulatory perspective. DIA Europe April Basel, Switzerland
Use of disease registries for benefitrisk evaluation of medicines: A regulatory perspective DIA Europe 2018-17-19 April Basel, Switzerland Presented by Xavier Kurz Head of Service Surveillance and Epidemiology
More informationIssue 7/ Jul - Sept 2012
The Hong Kong Association of the Pharmaceutical Industry Issue 7/9 2012 Jul - Sept 2012 In This Issue September CEO Luncheon Meeting with Dr. Ko Wing-man Joint Event with the Drug Office Visit to Macau
More informationCMDv/BPG/002. BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP)
BEST PRACTICE GUIDE for Veterinary Decentralised Procedure (DCP) Edition number: 05 Edition date: 7 November 2013 Implementation date: 6 February 2006 CMDv Secretariat: 7 Westferry Circus, Canary Wharf,
More informationECG Peer Review: Status Report. Keith Leonard Director, OED1 Operations Evaluation Department Asian Development Bank June 2007
ECG Peer Review: Status Report Keith Leonard Director, OED1 Operations Evaluation Department Asian Development Bank June 2007 Status of Peer Review Proposal ECG task force visited IADB, EBRD and AsDB to
More informationGUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS
Doc. No. TFDA/DMC/MCER/---- TANZANIA FOOD AND DRUGS AUTHORITY GUIDELINES ON PROCEDURAL ASPECTS FOR APPLICATIONS FOR MARKETING AUTHORIZATION OF MEDICINAL PRODUCTS (Made under Section 52 (1) of the Tanzania
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Risk Assessment SOP-RES-002 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s)
More informationREGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION
REGISTRATION OF MEDICINES IN THE EURASIAN ECONOMIC UNION www.gratanet.com At the Pharmaceutical Forum of the EAEU and CIS countries held in Moscow in late February 2018, the Director of the Department
More informationLaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S.
LaTonya M. Mitchell District Director, Denver District Director Office of Regulatory Affairs Office of Global Regulatory Operations & Policy U.S. Food and Drug Administration 1 Office of the Commissioner
More informationStay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know
CDER SBIA Webinar Series Stay Compliant! Electronic Submission of Drug Master Files (DMFs) is MANDATORY starting May 5, 2017: What You Need to Know Jonathan Resnick, Project Management Officer Division
More informationAnnex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions
10 March 2017 Annex 2 to the HMA esubmission Roadmap: Implementation of mandatory use of ectd format for regulatory submissions Status: Final updated version adopted by the esubmission CMB Scope This annex
More informationAssessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria
15 March 2018 EMA/698917/2017 Stakeholders and Communication Division Assessment of patient, consumer and healthcare professional organisations compliance with EMA eligibility criteria 1. Introduction
More informationectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Disclaimer
ectd IV: It s Almost As Fun As Super Bowl XLIX DIA eregulatory and Intelligence Annual Conference Mark Gray FDA/CBER Senior Project Manager 1 Disclaimer Views expressed in this presentation are those of
More informationSJN DO CB Field Alert Reports. Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office
SJN DO CB Field Alert Reports Edwin Ramos Director of Compliance Food and Drug Administration San Juan District Office SJN DO Mission Assuring that safe and effective drugs are available to the public
More informationTopical Peer Review 2017 Ageing Management of Nuclear Power Plants
HLG_p(2016-33)_348 Topical Peer Review 2017 Ageing Management of Nuclear Power Plants Terms of Reference for Topical Peer Review Process This paper provides the terms of reference for the peer review of
More informationBIMO Program Update an operational perspective
BIMO Program Update an operational perspective Clinical Trials Summit San Juan, Puerto Rico May 9, 2018 Anne E. Johnson Program Division Director FDA/ORA/OBIMO Division I (East) 1 Objectives Program Alignment
More informationComputer Validation Initiative Committee Membership Requirements
SOP No. CV-02.03 Supersedes SOP No. CV-02.02 Effective Page 1 of 5 Original Issue 18 February 2002 Retirement Computer Validation Initiative Committee Membership Requirements 1. Significant Change(s) from
More informationDefinitions: In this chapter, unless the context or subject matter otherwise requires:
CHAPTER 61-02-01 Final Copy PHARMACY PERMITS Section 61-02-01-01 Permit Required 61-02-01-02 Application for Permit 61-02-01-03 Pharmaceutical Compounding Standards 61-02-01-04 Permit Not Transferable
More informationHealth Technology Assessment (HTA) Good Practices & Principles FIFARMA, I. Government s cost containment measures: current status & issues
KeyPointsforDecisionMakers HealthTechnologyAssessment(HTA) refers to the scientific multidisciplinary field that addresses inatransparentandsystematicway theclinical,economic,organizational, social,legal,andethicalimpactsofa
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Sponsorship SOP-RES-001 Version Number 3 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov 2018 Author(s) Reviewer(s) Teresa
More informationResearch Audits PGR. Effective: 12/04/2013 Reviewed: 12/04/2015. Name of Associated Policy: Palmetto Health Administrative Research Review
Effective: 12/04/2013 Reviewed: 12/04/2015 Name of Associated Policy: Palmetto Health Administrative Research Review Definitions Responsible Positions Equipment Needed Procedure Steps, Guidelines, Rules,
More informationClinical Research Professionals
Training & Resources for Clinical Research Professionals Course & Publications Catalog January July 2016 In-Person and Web-Based Training Courses, Customized Training, elearning and Publications for Clinical
More informationGDUFA II IR and DR Letters Michael Folkendt, M.S.
GDUFA II IR and DR Letters Michael Folkendt, M.S. Associate Director for Regulatory Affairs Office of Program and Regulatory Operations Office of Pharmaceutical Quality, CDER, FDA 2017 AAM Fall Technical
More informationDEPARTMENT OF SCIENCE & TECHNOLOGY (DST) and RESEARCH COUNCIL OF NORWAY (RCN)
DEPARTMENT OF SCIENCE & TECHNOLOGY (DST) and RESEARCH COUNCIL OF NORWAY (RCN) CALL FOR PROPOSALS on Energy research (2018) Last date for submission of proposals: For Norwegian applicants: 14 February 2018
More informationEuropean Medicines Agency guidance for applicants seeking scientific advice and protocol assistance
30 June 2017 EMA/4260/2001 Rev. 9 Product Development Scientific Support Department European Medicines Agency guidance for applicants seeking scientific advice and This guidance document addresses a number
More informationCWE Flow-based Market Coupling Project. at EMART Energy 2012
CWE Flow-based Market Coupling Project at EMART Energy 2012 1 Agenda Flow Based Market Coupling: reminder of essentials From ATC Market Coupling to Flow Based Market Coupling: key milestones and main impacts
More informationOUTSOURCING SURVEY. This year we had 315 industry professionals respond
2016 Tim Wright Editor OUTSOURCING SURVEY Herein are the results of our 2016 Annual Outsourcing Survey, where we call on you, the readers, to help us benchmark the state of the pharmaceutical outsourcing
More informationSafeguarding public health. The New PV Legislation its Impact on PV & MI
Safeguarding public health The New PV Legislation its Impact on PV & MI Sarah Vaughan - MHRA PIPA 2013 Manager s Meeting 13 th February 2013 Content Scope of change Key areas - ADR reporting - DDPS to
More information